Specializing in immume moderators designed to use the body's own immune system to fight disease, Gliknik, Inc is a biopharmaceutical company developings novel therapies for patients with cancers and immune disorders. With other pipeline therapies are still in pre-clinical stages, Gliknik's lead candidate, GL-0817, an oral cancer treatment, was undergoing phase IIb trials. Gliknik signed licensing and collaboration agreements with Pfizer and Brace Pharmaceutical, the American investing arm of Brazillian pharmaceutical company EMS. The firm has successfullt raised a significant volume of VC to support the effort.
